Document Type : Original Article
Authors
1
Department of Otolaryngology, faculty of medicine, Cairo University. Egypt.
2
Department of Otolaryngology, faculty of medicine, Al-Azhar University. Egypt.
3
Department of Otolaryngology, Railway Hospital, Cairo, Egypt
4
Department of Otolaryngology, faculty of medicine, Cairo University, Egypt
10.21608/aimj.2025.394383.2570
Abstract
Introduction: Dupilumab is a biologic agent and a monoclonal antibody that blocks receptors on IL4,13. It’s indicated in specific cases of CRSwNP, it decreases symptoms, polyps’ size and opacification in CT.
Aim: This study aimed to assess the effect of dupilumab on Egyptian patients with chronic rhinosinusitis with nasal polyps.
Methods: This is a triple-centre prospective cohort study, conducted on 50 adult patients of both sexes with chronic rhinosinusitis with nasal polyps that fulfil EPOS 202077 criteria for case selection for biologic treatment at the otolaryngology departments of Cairo and Al-Azhar Universities and Railway hospital from October 2024 to May 2025. The study was approved by the ethical committee of the Faculty of Medicine, Cairo University, Egypt, with IRB number (N-396-2024).
Results: Before treatment, most patients (58%) had a maximum score of 24, with no patients scoring below 14. After six months, the most common post-treatment score was 16, recorded in 44% of patients, with a highly significant difference compared to baseline (P < 0.0001).
Conclusion: Dupilumab is an effective biologic treatment for chronic rhinosinusitis with nasal polyps with type 2 inflammation. It showed a significant decrease in the CT scoring system in all sample sizes, with improved quality of life.
Keywords
)
View on SCiNiTO